hl7

{"resourceType":"PlanDefinition","id":"KDN5","text":{"status":"additional","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \n      \u003ctable style\u003d\"width: 100%;\"\u003e\n        \n        \u003ctr\u003e\n          \n          \u003ctd\u003e\n            \n            \n            \u003cdiv style\u003d\"width: 200px; height: 100px; vertical-align: top;\"\u003eNational Comprehensive Cancer Network\u003c/div\u003e\n          \n          \u003c/td\u003e\n          \n          \u003ctd\u003e\n            \n            \u003ch3\u003eChemotherapy Order Template\u003c/h3\u003e\n            \n            \u003ch1\u003eKidney Cancer\u003c/h1\u003e\n            \n            \u003ch2\u003eGemcitabine/CARBOplatin\u003c/h2\u003e\n          \n          \u003c/td\u003e\n          \n          \u003ctd style\u003d\"text-align: right; vertical-align: top;\"\u003eKDN5\u003c/td\u003e\n        \n        \u003c/tr\u003e\n      \n      \u003c/table\u003e\n      \n      \u003ctable style\u003d\"width: 100%; border-top: 1px solid; border-bottom: 1px solid;\"\u003e\n        \n        \u003ctr\u003e\n          \n          \u003ctd style\u003d\"width: 33%; border-right: 1px solid; vertical-align: top\"\u003e\n            \n            \u003ch4\u003eINDICATION:\u003c/h4\u003e\n            \n            \u003cp\u003eMetastatic or Relapsed – Collecting Duct/Medullary Subtypes\u003c/p\u003e\n          \n          \u003c/td\u003e\n          \n          \u003ctd style\u003d\"width: 34%; border-right: 1px solid; vertical-align: top\"\u003e\n            \n            \u003ch4\u003eREFERENCES:\u003c/h4\u003e\n            \n            \u003col\u003e\n              \n              \u003cli\u003e\n                \u003ca href\u003d\"http://www.example.org/professionals/physician_gls/PDF/kidney.pdf\"\u003eNCCN Guidelines® for Kidney Cancer. V.3.2015.\u003c/a\u003e\n              \u003c/li\u003e\n              \n              \u003cli\u003e\n                \u003ca href\u003d\"http://www.ncbi.nlm.nih.gov/pubmed?term\u003d%22The+Journal+of+urology%22%5BJour%5D+AND+1698%5Bpage%5D+AND+2007%5Bpdat%5D+AND+Oudard+S%5Bauthor%5D\"\u003eOudard S, et al. \n                  \u003cem\u003eJ Urol\u003c/em\u003e. 2007;177(5):1698-702.\n                \u003c/a\u003e\n                \u003csup\u003e\n                  \n                  \u003ca href\u003d\"http://www.example.org/OrderTemplates/PDF/appendix_E.pdf\"\u003ea\u003c/a\u003e\n                \u003c/sup\u003e\n              \n              \u003c/li\u003e\n            \n            \u003c/ol\u003e\n          \n          \u003c/td\u003e\n          \n          \u003ctd style\u003d\"width: 33%; vertical-align: top\"\u003e\n            \n            \u003ch4\u003eNCCN SUPPORTIVE CARE:\u003c/h4\u003e\n            \n            \u003col\u003e\n              \n              \u003cli\u003e\n                \n                \u003ci\u003eEmetic Risk:\u003c/i\u003e\n                \n                \u003ctable\u003e\n                  \n                  \u003ctr\u003e\n                    \n                    \u003ctd\u003eDay 1\u003c/td\u003e\n                    \n                    \u003ctd\u003eModerate\u003c/td\u003e\n                  \n                  \u003c/tr\u003e\n                  \n                  \u003ctr\u003e\n                    \n                    \u003ctd\u003eDay 8\u003c/td\u003e\n                    \n                    \u003ctd\u003eLow\u003c/td\u003e\n                  \n                  \u003c/tr\u003e\n                \n                \u003c/table\u003e\n              \n              \u003c/li\u003e\n              \n              \u003cli\u003e\n                \n                \u003ci\u003eFever Neutropenia Risk:\u003c/i\u003e\n                \u003cbr/\u003e\n                Refer to \n                \u003ca href\u003d\"http://www.example.org/professionals/physician_gls/PDF/myeloid_growth.pdf\"\u003eNCCN Guidelines for Myeloid Growth Factors. V.2.2014\u003c/a\u003e\n              \n              \u003c/li\u003e\n            \n            \u003c/ol\u003e\n          \n          \u003c/td\u003e\n        \n        \u003c/tr\u003e\n      \n      \u003c/table\u003e\n      \n      \n      \u003ch4\u003eCHEMOTHERAPY REGIMEN\u003c/h4\u003e\n      \n      \u003cp\u003e\n        \n        \u003ci\u003e21-day cycle for 6 cycles\u003c/i\u003e\n      \n      \u003c/p\u003e\n      \n      \u003cul\u003e\n        \n        \u003cli\u003eGemcitabine 1250 mg/m\n          \u003csup\u003e2\u003c/sup\u003e IV over 30 minutes on Days 1 and 8\n        \u003c/li\u003e\n        \n        \u003cli\u003eCARBOplatin AUC 5 IV over 30 minutes on Day 1\u003c/li\u003e\n      \n      \u003c/ul\u003e\n    \n    \u003c/div\u003e"},"contained":[{"resourceType":"ActivityDefinition","id":"1111","status":"draft","productCodeableConcept":{"coding":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"12574","display":"gemcitabine"}],"text":"gemcitabine"},"dosage":[{"text":"1250 mg/m² IV over 30 minutes","timing":{"repeat":{"duration":30,"durationUnit":"min"}},"route":{"text":"IV"},"doseAndRate":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/dose-rate-type","code":"ordered","display":"Ordered"}]},"doseQuantity":{"value":1250,"unit":"mg/m²"}}]}]},{"resourceType":"ActivityDefinition","id":"2222","status":"draft","productCodeableConcept":{"coding":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"40048","display":"Carboplatin"}],"text":"CARBOplatin"},"dosage":[{"text":"AUC 5 IV over 30 minutes","timing":{"repeat":{"duration":30,"durationUnit":"min"}},"route":{"text":"IV"},"doseAndRate":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/dose-rate-type","code":"ordered","display":"Ordered"}]},"doseQuantity":{"extension":[{"url":"http://example.org/fhir/AUC-dose","valueInteger":5}]}}]}]}],"identifier":[{"system":"http://example.org/ordertemplates","value":"KDN5"}],"version":"1","name":"GemcitabineCARBOplatin","title":"Gemcitabine/CARBOplatin","type":{"text":"Chemotherapy Order Template"},"status":"draft","experimental":true,"publisher":"National Comprehensive Cancer Network, Inc.","description":"Gemcitabine/CARBOplatin","useContext":[{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/usagecontext-group","valueString":"A"}],"code":{"system":"http://example.org/fhir/CodeSystem/indications","code":"treamentSetting-or-diseaseStatus"},"valueCodeableConcept":{"text":"Metastatic"}},{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/usagecontext-group","valueString":"A"}],"code":{"system":"http://example.org/fhir/CodeSystem/indications","code":"disease-or-histology"},"valueCodeableConcept":{"text":"Collecting Duct/Medullary Subtypes"}},{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/usagecontext-group","valueString":"A"}],"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus"},"valueCodeableConcept":{"text":"Kidney Cancer"}},{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/usagecontext-group","valueString":"B"}],"code":{"system":"http://example.org/fhir/CodeSystem/indications","code":"treatmentSetting-or-diseaseStatus"},"valueCodeableConcept":{"text":"Relapsed"}},{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/usagecontext-group","valueString":"B"}],"code":{"system":"http://example.org/fhir/CodeSystem/indications","code":"disease-or-histology"},"valueCodeableConcept":{"text":"Collecting Duct/Medullary Subtypes"}},{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/usagecontext-group","valueString":"B"}],"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus"},"valueCodeableConcept":{"text":"Kidney Cancer – Collecting Duct/Medullary Subtypes - Metastatic"}}],"copyright":"All rights reserved.","approvalDate":"2016-07-27","lastReviewDate":"2016-07-27","author":[{"name":"Lee Surprenant"}],"relatedArtifact":[{"type":"derived-from","display":"NCCN Guidelines for Kidney Cancer. V.2.2016","document":{"url":"http://www.example.org/professionals/physician_gls/PDF/kidney.pdf"}},{"type":"citation","_type":{"extension":[{"url":"http://example.org/fhir/regimenReferenceType","valueCode":"a"}]},"citation":"Oudard S, et al. J Urol. 2007;177(5):1698-702","document":{"url":"http://www.ncbi.nlm.nih.gov/pubmed/17437788"}}],"action":[{"selectionBehavior":"exactly-one","action":[{"selectionBehavior":"all","action":[{"groupingBehavior":"sentence-group","selectionBehavior":"exactly-one","action":[{"id":"cycle-definition-1","textEquivalent":"21-day cycle for 6 cycles","timingTiming":{"repeat":{"count":6,"duration":21,"durationUnit":"d"}},"action":[{"id":"action-1","extension":[{"url":"http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle","extension":[{"url":"day","valueInteger":1},{"url":"day","valueInteger":8}]}],"textEquivalent":"Gemcitabine 1250 mg/m² IV over 30 minutes on days 1 and 8","definitionCanonical":"#1111"},{"id":"action-2","extension":[{"url":"http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle","extension":[{"url":"day","valueInteger":1}]}],"textEquivalent":"CARBOplatin AUC 5 IV over 30 minutes on Day 1","relatedAction":[{"targetId":"action-1","relationship":"concurrent-with-start"}],"definitionCanonical":"#2222"}]}]}]}]}],"meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v3-ActReason","code":"HTEST","display":"test health data"}]}}